Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

4.490

-0.120 (-2.60%)

At close: Mar 13, 2026, 4:00 PM EDT

4.460

-0.030 (-0.67%)

After-hours: Mar 13, 2026, 5:44 PM EDT

Taysha Gene Therapies Employees

Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.

Employees

73

Change (1Y)

21

Growth (1Y)

40.38%

Revenue / Employee

$86,438

Profits / Employee

-$1,368,890

Market Cap

1.23B

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2024	73	21	40.38%
Dec 31, 2023	52	-13	-20.00%
Dec 31, 2022	65	-113	-63.48%
Dec 31, 2021	178	140	368.42%
Dec 31, 2020	38	-	-

Related Stocks

Company Name	Employees
Immatics	645
EyePoint	214
Monte Rosa Therapeutics	147
Precigen	143
MoonLake Immunotherapeutics	130
Septerna	130
Olema Pharmaceuticals	122
DBV Technologies	117

Employee Rankings

TSHA News

2 days ago - Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - GlobeNewsWire
8 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
7 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
2 months ago - Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewsWire
4 months ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
4 months ago - Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
4 months ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
5 months ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire